NCT06313996View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

October 16, 2031

Study Completion Date

October 16, 2031

Conditions
Relapsed or Refractory Follicular Lymphoma
Interventions
DRUG

Cyclophosphamide

Specified dose on specified days

DRUG

Doxorubicin

Specified dose on specified days

DRUG

Vincristine

Specified dose on specified days

DRUG

Rituximab

Specified dose on specified days

DRUG

Prednisone

Specified dose on specified days

DRUG

Bendamustine

Specified dose on specified days

DRUG

Lenalidomide

Specified dose on specified days

DRUG

Fludarabine

Specified dose on specified days

DRUG

Liso-cel

Specified dose on specified days

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

INDUSTRY

NCT06313996 - A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | Biotech Hunter | Biotech Hunter